Antares Pharma, Inc. (AMEX:AIS), today announced that it will report 2008 first quarter financial results on Thursday, May 15, 2008, before the open of the U.S. financial markets.
Jack E. Stover, President and Chief Executive Officer, and other members of Antares’ senior management will provide a company update and review 2008 first quarter results via webcast and conference call on Thursday, May 15, 2008, at 8:30 a.m. ET. The webcast of this call will be available from the investors/media section of the Company's web site, www.antarespharma.com, and will be archived for 30 days. Alternatively, callers may participate in the conference call by dialing 800-762-8932 (domestic) or 480-629-9031 (international). Participants should reference the Antares Pharma conference call. Webcast and telephone replays of the conference call will be available approximately two hours after the completion of the call through Friday, May 23, 2008. To access the replay, callers should dial 800-406-7325 (domestic) or 303-590-3030 (international). The passcode is 3876024.
About Antares Pharma
Antares Pharma is a specialized pharma product development company committed to improving pharmaceuticals through its patented drug delivery systems. Antares has three validated systems: the ATDTM Advanced Transdermal Gel Delivery system, subcutaneous injection technology platforms including VibexTM disposable pressure assisted auto injectors, ValeoTM/Vision® reusable needle-free injectors and pen injectors; and Easy TecTM oral disintegrating tablets (ODT). Two of the systems have generated FDA approved products. Antares Pharma leverages its multiple drug delivery systems to add value to existing drugs and to create new products. The Company’s products are engineered to improve safety and efficacy profiles by minimizing dosing and reducing side effects while enabling improved patient compliance. Antares Pharma has corporate headquarters in Ewing, New Jersey, with subsidiaries performing research, development, manufacturing and product commercialization activities in Minneapolis, Minnesota and Basel, Switzerland.
Safe Harbor Statement
The 2008 results press and conference call will contain forward-looking statements, within the meaning of the "Safe Harbor" provisions of The Private Securities Litigation Reform Act of 1995, that involve significant risks and uncertainties, including those discussed in the release and others that can be found in the “Risk Factors” section of Antares’ Annual Report on Form 10-K for the year ended December 31, 2007, and in Antares’ periodic reports on Form 10-Q and other filings made with the Securities and Exchange Commission. Antares is providing the information contained in the press release and conference call as of the date of the release and does not undertake any obligation to update any forward-looking statements contained as a result of new information, future events or otherwise. The Company cautions investors not to place undue reliance on the forward-looking statements contained in the press release or the conference call. No forward-looking statement can be guaranteed, and actual events and results may differ materially from those projected.
Contacts:
Stephanie M. Baldwin
Senior Manager,
Investor Relations
609-359-3032
sbaldwin@antarespharma.com
